Two DNA methyltransferase (DNMT) inhibitors, decitabine and azacytidine, have been approved by the FDA for clinical use in the treatment of myelodysplastic syndrome and acute myeloid leukemia [103]. Here, DNMT1 is linked to myelodysplastic syndrome.